Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325021 | 0.90 | NLRP3 (0.49) | NLRP3P2RX3KMT2AUSP2GPR139 | |
| SCHEMBL25950155 | 0.88 | NLRP3 (0.51) | NLRP3P2RX3KMT2AUSP2 | |
| SCHEMBL31325030 | 0.86 | NLRP3 (0.49) | NLRP3P2RX3KMT2AUSP2MAPT | |
| SCHEMBL25949976 | 0.83 | NLRP3 (0.43) | NLRP3P2RX3KMT2AUSP2 | |
| SCHEMBL31325029 | 0.83 | NLRP3 (0.43) | NLRP3P2RX3KMT2AUSP2 | |
| SCHEMBL25332425 | 0.81 | NLRP3 (0.40) | NLRP3 | |
| SCHEMBL31325035 | 0.80 | NLRP3 (0.59) | NLRP3P2RX3KMT2AMERTKUSP2 | |
| SCHEMBL25950135 | 0.78 | TSHR (0.50) | P2RX3KMT2AUSP2 | |
| SCHEMBL31325019 | 0.78 | NLRP3 (0.63) | NLRP3KMT2AUSP2GPR139MAPT | |
| SCHEMBL31325023 | 0.77 | NLRP3 (0.62) | NLRP3KMT2AUSP2GPR139MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2025-02-27 | — | — | US | disclosed |
| CN-118922421-A | Bicyclic phthalazin-1 (2H) -one derivatives and related uses | 诺瑟拉有限公司 | 2024-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | IL1B, NLRP3, IL1A | NLRP3 2/4885P2RX3 354/4885KMT2A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.